"Genentech is a tremendously exciting place to work. Biotherapeutic development is constantly evolving, so I am always on a learning curve, building on experience and continuing to gather new information about the field. I really enjoy working in a cross-functional environment with terrific colleagues who are subject matter experts in a wide range of scientific disciplines."
I joined Genentech as a Scientist in 1994 after a PhD and postdoctoral training in molecular and cellular endocrinology and in the clinical diagnostics industry. I initially generated bioanalytical methods and data to support molecules in our endocrine portfolio. Since then, I have had the opportunity to develop bioanalytical methods and/or strategies to enable IND, BLA, NDA and related filings for most of the approved biotherapeutics in our portfolio. I also learned a tremendous amount about drug development during my time as Pharmacology Team Leader for a particular medicine. I think that the most rewarding aspect of my job is developing medicines that make it into the clinic for the treatment and management of life-threatening diseases.
I currently run the Core Biophysical Characterization & Reagent Facility in BioAnalytical Sciences (BAS), and I also lead the BAS review group that endorses bioanalytical strategies for all protein therapeutics in the gRED drug development pipeline.
Development Sciences (DevSci), does translational drug development work for gRED. Within DevSci, BAS generates bioanalytical methods and data to characterize pharmacokinetics and pharmacodynamics of our molecules along with any immune responses. DevSci is a highly collaborative work environment, and I interact with colleagues who are experts in a wide range of drug development disciplines In addition I consult, and actively participate with teams across the Roche/Genentech organization and interact with Health Authorities on strategic and technical aspects of bioanalysis.
Externally, I am a member of the United States Pharmacopeia Immunogenicity Testing Expert Panel, and I also chaired the American Association of Pharmaceutical Scientists Therapeutic Protein Immunogenicity Focus Group from 2012-2014.